Full Press Release Details
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
Please find enclosed a Press Release on
"Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the
This is for your information.
For Dr. Reddy's Laboratories Limited
| /s/ K Randhir Singh | ||
| K Randhir Singh | ||
| Company Secretary & Compliance Officer |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | Investor relationS AMIT AGARWAL amita@drreddys.com | Media relationS USHA IYER ushaiyer@drreddys.com |
Laboratories announces the launch of the generic version of
Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market
Hyderabad, India, June 14, 2022
Hyderabad, India and Princeton, NJ, USA.
June 14, 2022 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its
subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Dr. Reddy's Sorafenib
Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar (sorafenib) Tablets in the U.S. market following the approval
by the U.S. Food and Drug Administration (USFDA).
"We are pleased to launch this important
generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients," says
Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories Inc.
Dr. Reddy's Sorafenib Tablets, USP,
are available in 200 mg tablets in bottle count sizes of 120.
Please click here: https://drreddys.com/pil/Sorafenib-Tablets-Leaflet.pdf
to see the full prescribing information.
About Dr. Reddy's: Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed
to providing affordable and innovative medicines for healthier lives. Dr. Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas
of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates
in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,
log on to: www.drreddys.com
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management's current views and
assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ
materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of
context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those
in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality
and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and
regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including
related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers',
products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness,
including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities
and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections
of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information